尼帕病毒(NiV)副粘病毒科亨氏病毒属的人畜共患病毒,1998年在马来西亚出现,后来在全球传播。根据严重程度和早期用药,患病患者可能有40-70%的死亡机会。最近在喀拉拉邦(印度)爆发了一种新的MCL-19-H-1134分离株。目前,没有疫苗,强调迫切需要采取决定性的补救措施。我们的研究旨在通过分析NiV的蛋白质组开发针对NiV的亚单位疫苗。NiV基因组和蛋白质组序列从NCBI数据库获得。基于基因组比对构建了系统进化树。T细胞,辅助性T细胞,使用NetCTL-1.2,NetMHCIIPan-4.1和IEDB服务器从蛋白质序列中预测B细胞表位,分别。选择人受体的高亲和力表位以构建多表位疫苗(MEV)。这些表位的抗原性,毒性,使用VaxiJen评估了过敏原性,AllergenFP-v.1.0和AllergenFP算法。使用PyRx和ClusPro分析与特定受体的分子相互作用。使用PyMOL和LigPlot对氨基酸相互作用进行可视化和分析。使用C-ImmSim进行免疫模拟以评估由MEV引发的免疫应答。最后,使用SnapGene工具将疫苗cDNA插入pET28a(+)表达载体,用于大肠杆菌宿主中的计算机克隆。即将爆发的可能性不容忽视。亚单位疫苗更具成本效益和时间效率。通过额外的体外和体内验证,该疫苗可能成为预防NiV疾病的优良措施。
■在线版本包含补充材料,可在10.1007/s40203-024-00246-9获得。
The Nipah virus (NiV), a zoonotic virus in the Henipavirus genus of the Paramyxoviridae family, emerged in Malaysia in 1998 and later spread globally. Diseased patients may have a 40- 70% chance of fatality depending on the severity and early medication. The recent outbreak of NiV was reported in Kerala (India) by a new strain of MCL-19-H-1134 isolate. Currently, no vaccines are available, highlighting the critical need for a conclusive remedy. Our study aims to develop a subunit vaccine against the NiV by analyzing its proteome. NiV genome and proteome sequences were obtained from the NCBI database. A phylogenetic tree was constructed based on genome alignment. T-cell, helper T-cell, and B-cell epitopes were predicted from the protein sequences using NetCTL-1.2, NetMHCIIPan-4.1, and IEDB servers, respectively. High-affinity epitopes for human receptors were selected to construct a multi-epitope vaccine (MEV). These epitopes\' antigenicity, toxicity, and allergenicity were evaluated using VaxiJen, AllergenFP-v.1.0, and AllergenFP algorithms. Molecular interactions with specific receptors were analyzed using PyRx and ClusPro. Amino acid interactions were visualized and analyzed using PyMOL and LigPlot. Immuno-simulation was conducted using C-ImmSim to assess the immune response elicited by the MEV. Finally, the vaccine cDNA was inserted into the pET28a(+) expression vector using SnapGene tool for in silico cloning in an E. coli host. The potential for an imminent outbreak cannot be overlooked. A subunit vaccine is more cost-effective and time-efficient. With additional in vitro and in vivo validation, this vaccine could become a superior preventive measure against NiV disease.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40203-024-00246-9.